Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $59 to $63.
October 27, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Blueprint Medicines and raises the price target from $59 to $63.
The news is directly related to Blueprint Medicines. The raised price target by Morgan Stanley indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100